Literature DB >> 18627332

Morphine-6-glucuronide: potency and safety compared with morphine.

Eveline L A van Dorp1, Aurora Morariu, Albert Dahan.   

Abstract

BACKGROUND: In contemporary medicine, morphine remains the drug of choice in the treatment of severe postoperative pain. Nevertheless, morphine has several side effects, which can seriously compromise its analgesic effectiveness and the patient safety/compliance. The search for opioid analgesics with a better side-effect profile than morphine has led to a morphine metabolites, morphine-6-glucuronide (M6G).
OBJECTIVE: The objectives of the current paper are to give an overview of the analgesic properties of M6G, assess the dose range at which it produces equianalgesia to morphine and explore its side-effect profile.
METHODS: A review of published clinical studies (Phase II - III) on M6G in the treatment of experimental and clinical pain is given. RESULTS/
CONCLUSIONS: M6G > 0.2 mg/kg is an effective analgesic with a slower onset but longer duration of action (> 12 h) compared with morphine. Side effects, most importantly postoperative nausea and vomiting, occur less frequent after M6G treatment. M6G is an attractive alternative to morphine in the treatment of severe postoperative pain.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18627332     DOI: 10.1517/14656566.9.11.1955

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  11 in total

Review 1.  Peripheral mechanisms of pain and analgesia.

Authors:  Christoph Stein; J David Clark; Uhtaek Oh; Michael R Vasko; George L Wilcox; Aaron C Overland; Todd W Vanderah; Robert H Spencer
Journal:  Brain Res Rev       Date:  2008-12-31

Review 2.  First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics.

Authors:  Baojian Wu; Kaustubh Kulkarni; Sumit Basu; Shuxing Zhang; Ming Hu
Journal:  J Pharm Sci       Date:  2011-04-11       Impact factor: 3.534

Review 3.  Regioselective sulfation and glucuronidation of phenolics: insights into the structural basis.

Authors:  Baojian Wu; Sumit Basu; Shengnan Meng; Xiaoqiang Wang; Ming Hu
Journal:  Curr Drug Metab       Date:  2011-11       Impact factor: 3.731

4.  Opioids as an alternative to amide-type local anaesthetics for intra-articular application.

Authors:  Irina Ickert; Monika Herten; Melanie Vogl; Christoph Ziskoven; Christoph Zilkens; Rüdiger Krauspe; Jörn Kircher
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2014-05-04       Impact factor: 4.342

5.  Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active.

Authors:  Sarah M Brown; Michael Holtzman; Thomas Kim; Evan D Kharasch
Journal:  Anesthesiology       Date:  2011-12       Impact factor: 7.892

6.  Cyclosporine-inhibitable blood-brain barrier drug transport influences clinical morphine pharmacodynamics.

Authors:  Konrad Meissner; Michael J Avram; Viktar Yermolenka; Amber M Francis; Jane Blood; Evan D Kharasch
Journal:  Anesthesiology       Date:  2013-10       Impact factor: 7.892

7.  Chemical and enzyme-assisted syntheses of norbuprenorphine-3-β-D-glucuronide.

Authors:  Jinda Fan; Sarah M Brown; Zhude Tu; Evan D Kharasch
Journal:  Bioconjug Chem       Date:  2011-03-24       Impact factor: 4.774

8.  Liquid chromatography-tandem mass spectrometry for analysis of intestinal permeability of loperamide in physiological buffer.

Authors:  Miriam S Rubelt; Salah Amasheh; Thomas Grobosch; Christoph Stein
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

Review 9.  The pharmacogenomics of pain management: prospects for personalized medicine.

Authors:  Sonya Ting; Stephan Schug
Journal:  J Pain Res       Date:  2016-02-10       Impact factor: 3.133

10.  Comparative Analysis of Gelsemine and Gelsemium sempervirens Activity on Neurosteroid Allopregnanolone Formation in the Spinal Cord and Limbic System.

Authors:  Christine Venard; Naoual Boujedaini; Ayikoe Guy Mensah-Nyagan; Christine Patte-Mensah
Journal:  Evid Based Complement Alternat Med       Date:  2011-06-16       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.